Related Experiment Video

Updated: Aug 22, 2026

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

Meropenem decreases serum level of valproic acid

Ergun Nacarkucuk1, Halil Saglam, Mehmet Okan

  • 1Department of Pediatrics, Division of Pediatric Neurology, Uludag University School of Medicine, Bursa, Turkey.

Pediatric Neurology
|September 8, 2004
PubMed

Insights

Concomitant meropenem therapy significantly lowers valproic acid levels in children, potentially to subtherapeutic ranges. However, valproic acid levels normalize after stopping meropenem, suggesting no need to change antiepileptic drugs if seizures are absent.

Area of Science:

  • Pediatric Pharmacology
  • Infectious Diseases
  • Neurology

Background:

  • Valproic acid is a widely used antiepileptic drug.
  • Meropenem is a broad-spectrum carbapenem antibiotic.
  • Previous studies indicated potential drug interactions between meropenem and valproic acid.

Observation:

  • This case report details three pediatric patients requiring concurrent valproic acid and meropenem.
  • Rapid decreases in serum valproic acid concentrations were observed in all three children during co-administration.
  • Valproic acid levels returned to therapeutic ranges shortly after meropenem discontinuation.

Findings:

  • Meropenem administration significantly reduces serum valproic acid levels in children.
  • The interaction leads to subtherapeutic valproic acid concentrations.
  • Discontinuation of meropenem allows for the restoration of therapeutic valproic acid levels.

Implications:

  • Concomitant meropenem use necessitates monitoring of valproic acid levels in pediatric patients.
  • Antiepileptic drug adjustments may not be required if seizure activity remains controlled.
  • Further research is needed to fully elucidate the pharmacokinetic interaction and establish clinical guidelines.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...